BR112018072729A8 - sistema genético reverso do vírus da zica - Google Patents

sistema genético reverso do vírus da zica Download PDF

Info

Publication number
BR112018072729A8
BR112018072729A8 BR112018072729A BR112018072729A BR112018072729A8 BR 112018072729 A8 BR112018072729 A8 BR 112018072729A8 BR 112018072729 A BR112018072729 A BR 112018072729A BR 112018072729 A BR112018072729 A BR 112018072729A BR 112018072729 A8 BR112018072729 A8 BR 112018072729A8
Authority
BR
Brazil
Prior art keywords
genetic system
reverse genetic
virus
zica virus
zica
Prior art date
Application number
BR112018072729A
Other languages
English (en)
Other versions
BR112018072729B8 (pt
BR112018072729A2 (pt
BR112018072729B1 (pt
Inventor
Shan Chao
Shi Pei-Yong
Xie Xuping
Original Assignee
The Board Of Regents Of The Univ Of Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The Univ Of Texas filed Critical The Board Of Regents Of The Univ Of Texas
Publication of BR112018072729A2 publication Critical patent/BR112018072729A2/pt
Publication of BR112018072729A8 publication Critical patent/BR112018072729A8/pt
Publication of BR112018072729B1 publication Critical patent/BR112018072729B1/pt
Publication of BR112018072729B8 publication Critical patent/BR112018072729B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

as modalidades da invenção são dirigidas a clones de dnac de comprimento total, estáveis, de uma cepa zikv de linhagem clínica, asiática. determinadas modalidades da invenção são dirigidas a ensaios de alto rendimento para o diagnóstico de vírus zikv e da dengue (denv).
BR112018072729A 2016-05-03 2017-05-03 Ensaio para detectar infecção por flavivírus, cassete de expressão de dna recombinante e genoma de flavivírus recombinante BR112018072729B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662330958P 2016-05-03 2016-05-03
US62/330.958 2016-05-03
US201762455846P 2017-02-07 2017-02-07
US62/455.846 2017-02-07
PCT/US2017/030810 WO2017192701A1 (en) 2016-05-03 2017-05-03 Reverse genetics system of zika virus

Publications (4)

Publication Number Publication Date
BR112018072729A2 BR112018072729A2 (pt) 2019-03-12
BR112018072729A8 true BR112018072729A8 (pt) 2020-06-09
BR112018072729B1 BR112018072729B1 (pt) 2022-05-17
BR112018072729B8 BR112018072729B8 (pt) 2023-01-10

Family

ID=60203375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072729A BR112018072729B8 (pt) 2016-05-03 2017-05-03 Ensaio para detectar infecção por flavivírus, cassete de expressão de dna recombinante e genoma de flavivírus recombinante

Country Status (3)

Country Link
US (1) US10533997B2 (pt)
BR (1) BR112018072729B8 (pt)
WO (1) WO2017192701A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254953B2 (en) 2018-04-18 2022-02-22 Utah State University Compositions and methods for zika virus characterization and vaccine development
CN112011518A (zh) * 2019-05-30 2020-12-01 中山大学 寨卡病毒zg01株反向遗传系统的构建及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601947A2 (en) 2002-10-31 2005-12-07 Health Research, Incorporated Diagnostic test for west nile virus
US7355033B2 (en) 2002-11-18 2008-04-08 Health Research, Inc. Screening for West Nile Virus antiviral therapy
WO2010022238A2 (en) 2008-08-21 2010-02-25 Health Research, Inc. Anti-flavivirus therapeutic
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
EP2980099A1 (en) * 2014-07-31 2016-02-03 Bernhard-Nocht-Institut für Tropenmedizin Compositions and methods for detecting flaviviridae infections

Also Published As

Publication number Publication date
US10533997B2 (en) 2020-01-14
BR112018072729B8 (pt) 2023-01-10
US20190120841A1 (en) 2019-04-25
BR112018072729A2 (pt) 2019-03-12
BR112018072729B1 (pt) 2022-05-17
WO2017192701A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
BR112017008976A2 (pt) ?composição, métodos de aumento da viscosidade de composições aquosas, de tratamento de material, de produção de dextrano e reação enzimática?
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
TR201901582T4 (tr) Kapsid
BR112018069225A2 (pt) sistema de endereçamento de alvo
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
EA202092435A2 (ru) Моноклональные антитела против bcma
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
CL2015000487A1 (es) Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
EA201690372A1 (ru) Азапиридоновые соединения и их применение
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
EA201590412A1 (ru) Композиции антител и их применения
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
BR112018006843A2 (pt) sistema de fluxo e métodos para contagem digital
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112017006680A2 (pt) variantes de vírus influenza a
MX2017008096A (es) Pestivirus.
CL2016003140A1 (es) Sistema de expresión génica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2017, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2680 DE 17/05/2022, QUANTO AO ITEM (73) NOME DO TITULAR.